Iberdomide: all 41 studies that test it

Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)Not yet recruitingNCT07727668Early Phase 1
• Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseRecruitingNCT07437963Phase 1/2
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingNCT06892522Phase 1/2
• Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple MyelomaRecruitingNCT06785415Phase 1/2
• Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering MyelomaRecruitingNCT06762769Phase 2
• Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMRecruitingNCT06518551Phase 1/2
• Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaRecruitingNCT06465316Phase 1
• Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaRecruitingNCT06348108Phase 1
• Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple MyelomaRecruitingNCT06107738Phase 2
• A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingNCT05583617Phase 1/2
• NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomideRecruitingNCT05558319Phase 3
• Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM PatientsRecruitingNCT05272826Phase 2
• Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple MyelomaRecruitingNCT04776395Phase 2
• A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus ErythematosusCompletedNCT03161483Phase 2Results posted
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple MyelomaActive, not recruitingNCT02773030Phase 1/2Results posted
• A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.CompletedNCT02185040Phase 2Results posted
• Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple MyelomaSuspendedNCT06232044Phase 1/2
• A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)Active, not recruitingNCT06215118Phase 1
• Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaSuspendedNCT06179888Phase 2
• A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult ParticipantsCompletedNCT05899738Phase 1
• A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT05827016Phase 3
• A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05560399Early Phase 1
• Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruitingNCT05392946Phase 1/2
• Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)Active, not recruitingNCT05354557Phase 2
• Study of Novel Regimens in Relapsed or Refractory Multiple MyelomaTerminatedNCT05289492Phase 1
• Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple MyelomaSuspendedNCT05199311Phase 1/2
• Iberdomide Maintenance Therapy in Patients With Multiple MyelomaActive, not recruitingNCT05177536Phase 2
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT05169515Phase 1
• A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Active, not recruitingNCT04998786Phase 2
• Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04975997Phase 3
• Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney FunctionCompletedNCT04933747Phase 1
• Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat LymphomaActive, not recruitingNCT04884035Phase 1
• Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM PatientsActive, not recruitingNCT04564703Phase 2
• Iberdomide Combined With Low-dose Cyclophosphamide and DexamethasoneActive, not recruitingNCT04392037Phase 2
• Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy SubjectsCompletedNCT03824678Phase 1
• Radiolabeled Study of CC-220 in Healthy Male SubjectsCompletedNCT03294603Phase 1
• A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult SubjectsCompletedNCT03135509Phase 1
• Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy SubjectsCompletedNCT02820935Phase 1
• A Phase 2 Study With CC-220 in Skin SarcoidosisWithdrawnNCT02192489Phase 2
• 3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 CapsuleCompletedNCT02034773Phase 1
• 2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy SubjectsCompletedNCT01733875Phase 1

← Iberdomide overview